The Kruskal-Wallis ANOVA was used to detect differences between groups in [DELTA](delta) pain-free walking distance on the treadmill exercise test (pre-treatment to post-treatment) and [DELTA] pain-free walking distance on the 6-minute walk test (pretreatment to post-treatment), as these data were not normally distributed.
Pain-free walking distance during the SMWT increased significantly in the CER and UBST groups compared with the CONT group after training (37 [+ or -] 47% v.
The mean MWD during the GTT was 317 m; pain-free walking distance was 98 m (Table I).
However, resting ABI did not correlate with MWD (r=0.08; p=0.3) or pain-free walking distance (r=-0.19; p=0.15) (Figs 2a and 2b); nor was there any relationship between post-exercise ABI and walking tolerance during the GTT.
After 6 months, the 209 patients treated with beraprost had a mean 82% increase in their pain-free walking distance, compared with a mean 53% increase in the placebo group, a statistically significant increase in the study's primary end point.